The agreements aim to strengthen medicine quality, patient safety and pharmaceutical research in India
The Pharmaceuticals portfolio and pipeline are more promising than perhaps ever before
The acquisition brings three established small-molecule drug substance facilities into Siegfried’s global network
Our company is prioritising deeper collaborations with CDMOs and biosimilar companies as part of its strategy to expand its footprint across India, Middle East, and Africa region
Deal includes 13 branded generic products across 55+ countries; acquisition expected to strengthen global anti-infective portfolio and expand regulated market presence
Extending production capabilities to the Americas helps reduce labor costs and inventory complexity for nutraceuticals and other industries while maintaining superior moisture control
Denosumab biosimilars approved in Canada to expand access for osteoporosis and cancer-related bone conditions
The investment will bring in cutting-edge downstream fermentation technology, strengthening the company’s contract manufacturing capabilities for drug substances
New formulation by Greenspace Herbs to target improved efficacy and lower dosage in curcumin supplements
Approval for Albuterol Sulfate inhalation aerosol enables Cipla Limited to enter the $1.5 billion U.S. albuterol market
Subscribe To Our Newsletter & Stay Updated
